Welcome to: Beijing Dongfang Baitai Biotechnology Co., Ltd.

Technology platform   Technology platform

Oriental Baitai truly places technological innovation at the heart of its competitive edge, achieving end-to-end integration across antibody R&D and the entire manufacturing process.

 

The company has established a research and development and industrialization technology platform centered on innovative antibody therapeutics. Leveraging an extensive portfolio of animal disease models and a range of cutting-edge analytical techniques, it has developed monoclonal antibodies, ADCs, and bispecific antibodies for the treatment of various malignancies, diabetes, respiratory disorders, and autoimmune diseases.

Independently developed and manufactured platform

Critical core technologies

 

It aims to leverage differentiated design and screening technologies at the antibody drug discovery stage, supported by cutting-edge domestic and international platforms for antibody process optimization and manufacturing. , enabling the large-scale translation and commercialization of high‑efficacy, high‑quality antibody therapeutics to address unmet clinical needs among patients both domestically and internationally.

We primarily achieve the goal of treating major diseases by identifying key targets of the immune system and thereby activating or suppressing it.

High-throughput antibody phage display screening technology

Using a well-established antibody phage‑display screening platform, it is possible to rapidly identify high‑affinity antibody molecules with favorable physicochemical properties and robust biological activity against diverse targets within a relatively short timeframe.

Antibody humanization technology

By aligning antibody amino acid sequences and employing three-dimensional structural homology modeling, humanized antibody molecules can be rapidly generated, exhibiting a high degree of humanization and excellent biological activity.

Technology for Constructing Engineered Cell Lines with High Expression

An engineering cell line construction platform with proprietary intellectual property has been established, enabling the rapid screening of engineered cell lines with high antibody expression. Moreover, these engineered cell lines exhibit excellent long-term stability, meeting the requirements of production at various scales.

Possesses CMC capabilities meeting international standards and GMP-compliant manufacturing capacity.

The company possesses internationally advanced antibody process development and manufacturing equipment, and on this foundation has established leading domestic and international platforms for antibody process optimization and production, enabling the high‑quality, large‑scale manufacturing of antibody therapeutics.

Innovative antibody R&D and production across multiple technology platforms

Leveraging deep integration of R&D expertise, we continuously scale the heights of cutting-edge biopharmaceutical development and maintain a comprehensive end-to-end biologics development platform.

Innovative Antibody Discovery Platform

Quality Control Platform

High-Expression Mammalian Cell Line Screening Platform

Process Optimization Platform

Monoclonal antibody development platform

Pilot-scale production platform

Bispecific Antibody Development Platform

Clinical Medicine Platform

Therapeutic Vaccine Development Platform

Clinical Execution Platform

Pharmacology and Toxicology Platform

Large-scale industrialization platform

Complete experimental instruments and equipment

Dongfang Baitai is equipped with a wide array of advanced, high-precision instruments and comprehensive supporting facilities, ensuring that its drug research and development and manufacturing processes meet stringent quality standards and operate with high efficiency.

Uncle High-Throughput Multifunctional Protein Stability Analyzer

AKTA Avant Protein Purification System

Monoclonal Cell Tracking Imaging System

Attune Nxt Flow Cytometer

MSD (Meso Scale Discovery)

Biomolecular Interaction Analyzer (Biacore)